Martin, Courtney published the artcileSemiautonomous Treatment Algorithm for the Management of Severe Hypertension in Pregnancy, Computed Properties of 21829-25-4, the main research area is pregnancy severe hypertension semiautonomous treatment algorithm management.
To evaluate whether implementation of a semiautonomous treatment algorithm was associated with improved compliance with American College of Obstetricians and Gynecologists guidelines for rapid administration of antihypertensive therapy in the setting of sustained severe hypertension. This was a single-center retrospective cohort study of admitted pregnant and postpartum patients treated for severe hypertension between Jan. 2017 and March 2020. The semiautonomous treatment algorithm, which included vital sign monitoring, blood pressure thresholds for diagnosis of severe hypertension, and automated order sets for recommended first-line antihypertensive therapy were implemented between May 2018 and March 2019. The primary outcomes were the administration of antihypertensive therapy within 15, 30 and 60 min of diagnosis of severe hypertension. Comparisons were made between the preimplementation, during implementation, and postimplementation groups using χ2. Anal. was limited to the first episode of severe hypertension treated. Statistical significance was defined as P<.05. In total, there were 959 obstetric patients treated for severe hypertension, with 373 (38.9%) treated preimplementation, 334 (34.8%) during implementation, and 252 (26.2%) after implementation. Treatment of severe hypertension within 15 min was 36.5% preimplementation, 45.8% during implementation, and 55.6% postimplementation (P = .001). Treatment within 30 min was 65.9% in the preimplementation group, 77.8% during implementation, and 79.0% in the postimplementation group (P = .004). There was no difference in percentage of patients treated within 60 min (86.3% before, 87.7% during and 92.9% after implementation, P = .12). Implementation of a semiautonomous treatment algorithm for severe hypertension was associated with a higher percentage of pregnant and postpartum patients receiving the first dose of antihypertensive therapy within 15 and 30 min. Implementation of similar algorithms for this and other obstetric indications may decrease time to appropriate therapy and help improve care equity. Obstetrics & Gynecology (Philadelphia, PA, United States) published new progress about Antihypertensives. 21829-25-4 belongs to class pyridine-derivatives, name is Dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate, and the molecular formula is C17H18N2O6, Computed Properties of 21829-25-4.